Aging is associated with complex immune dysfunction that contributes to the onset and progression of the “geriatric giants”, including frailty, sarcopenia, cognitive decline, falls, and incontinence. Central to these conditions is immunosenescence, marked by thymic involution, the loss of naïve T cells, T-cell exhaustion, impaired B-cell class switch recombination, and increased autoreactivity. Concurrently, innate immunity deteriorates due to macrophage, neutrophil, and NK cell dysfunction, while chronic low-grade inflammation—or “inflammaging”—amplifies systemic decline. Key molecular pathways such as NF-κB, mTOR, and the NLRP3 inflammasome mediate immune aging, interacting with oxidative stress, mitochondrial dysfunction, and epigenetic modifications. These processes not only impair infection control and vaccine responsiveness but also promote tissue degeneration and multimorbidity. This review explores emerging interventions—ranging from senolytics and immunonutrition to microbiome-targeted therapies and exercise—that may restore immune homeostasis and extend healthspan. Despite advances, challenges remain in translating immunological insights into clinical strategies tailored to older adults. Standardization in microbiome trials and safety optimization in senolytic therapies are critical next steps. Integrating geroscience into clinical care could help to mitigate the burden of aging-related diseases by targeting fundamental drivers of immune dysfunction.
Drug-induced anaphylaxis is a severe, potentially fatal hypersensitivity reaction triggered by various pharmacologic agents, including antibiotics, nonsteroidal anti-inflammatory drugs, and biologics. It involves a spectrum of immunologic and nonimmunologic mechanisms, ranging from classical IgE-mediated pathways to complement activation and direct mast cell stimulation via receptors such as Mas-related G-protein-coupled receptor member X2 (MRGPRX2). The clinical heterogeneity of anaphylaxis presents significant diagnostic challenges, often requiring a combination of clinical evaluation, laboratory biomarkers (eg, serum tryptase and histamine), in vitro tests (eg, basophil activation test and specific IgE test), skin testing, and in some cases, a gold-standard drug provocation test, to establish a definitive diagnosis. Emerging insights into phenotypes and endotypes—such as cytokine-release reactions and bradykinin-mediated responses—enable a more complex understanding of pathophysiological mechanisms, facilitating precision diagnostics and targeted interventions. Accurate risk stratification considers both drug-related and patient-related factors, including genetic polymorphisms and comorbidities. Management hinges on the prompt administration of intramuscular epinephrine, with supportive therapies tailored to the underlying mechanism. In select patients, desensitization and delabeling strategies may allow continued treatment with essential medications. This review provides a comprehensive synthesis of the current knowledge on the pathogenesis, clinical features, diagnostic approaches, and management strategies for drug-induced anaphylaxis and highlights areas for future research aimed at improving patient safety and therapeutic outcomes.
27 August 2024 in Current Internal Medicine Research and Practice Surabaya Journal
Autoimmune hemolytic anemia (AIHA) may indicate the first manifestation of systemic lupus erythematosus (SLE). It is estimated that the incidence of AIHA is around 10% in patients with SLE. The first-line therapy for AIHA is corticosteroids. Nevertheless, a second-line therapy may be considered if an adequate response is not obtained. Transfusion indication in AIHA patients do not differ from other types of anemia. These indications include the degree of hemolysis, the progression of anemia, and clinical symptoms. However, blood transfusion for AIHA patients is challenging due to the limited availability of serologically compatible blood. In addition, AIHA patients who receive transfusions have an increased risk of experiencing hemolytic transfusion reactions. In this paper, we aimed to present a case report on the diagnosis of AIHA in an SLE patient treated with second-line therapy and red blood cell transfusions. The patient was a 49-year-old woman who presented with the main complaint of swelling in both legs. According to the medical history, the patient experienced petechia, abdominal distension, body weakness, and weight gain. No reports of joint pain, diarrhea, constipation, fever, shortness of breath, or yellowish skin were made. Before being referred to Dr. Soetomo General Academic Hospital in Surabaya, Indonesia, the patient experienced high blood pressure and body swelling that were unresponsive to treatment. Once the diagnosis of AIHA was confirmed, the patient was set to receive second-line therapy and red blood cell transfusions. At the conclusion of the therapy, the patient exhibited favorable outcomes. Highlights: